{"id":360,"date":"2024-09-26T14:14:10","date_gmt":"2024-09-26T14:14:10","guid":{"rendered":"https:\/\/stgmevpro.wpenginepowered.com\/?page_id=360"},"modified":"2025-09-08T12:43:54","modified_gmt":"2025-09-08T12:43:54","slug":"trial-hcp","status":"publish","type":"page","link":"https:\/\/mevproclinicaltrials.com\/en-nz\/trial-hcp\/","title":{"rendered":"Trial HCP"},"content":{"rendered":"<div data-elementor-type=\"wp-page\" data-elementor-id=\"360\" class=\"elementor elementor-360\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-00e60df header-background e-flex e-con-boxed e-con e-parent\" data-id=\"00e60df\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-37dd70f e-con-full e-flex e-con e-child\" data-id=\"37dd70f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-b3cf64b elementor-widget__width-initial elementor-widget-tablet__width-inherit elementor-widget elementor-widget-heading\" data-id=\"b3cf64b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Pfizer MEVPRO Prostate Cancer Clinical Trials<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d8b7b5d hero-heading elementor-widget__width-initial elementor-widget-mobile__width-inherit elementor-widget-tablet__width-inherit elementor-widget elementor-widget-heading\" data-id=\"d8b7b5d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\">Help advance metastatic prostate cancer treatment research<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-28b8308 e-con-full e-flex e-con e-child\" data-id=\"28b8308\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-272fb55 e-flex e-con-boxed e-con e-parent\" data-id=\"272fb55\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24e7439 elementor-widget elementor-widget-heading\" data-id=\"24e7439\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Explore Pfizer\u2019s MEVPRO Clinical Trials as potential options for your patients<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-357189b4 smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"357189b4\" data-element_type=\"container\" data-e-type=\"container\" id=\"MEVPRO-1\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-564190de e-con-full e-flex e-con e-child\" data-id=\"564190de\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5211ffb1 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5211ffb1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Not yet recruiting<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88646db elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"88646db\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Recruiting<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1be04a7e textBreast elementor-widget elementor-widget-text-editor\" data-id=\"1be04a7e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-1\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-54b00164 elementor-widget elementor-widget-text-editor\" data-id=\"54b00164\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tFor your patients with abiraterone-resistant metastatic prostate cancer\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-12eb84b2 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"12eb84b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06551324?term=NCT06551324&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1a8227d1 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"1a8227d1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&#038;EUCT=2024-511650-50-00\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7103bdce e-con-full e-flex e-con e-child\" data-id=\"7103bdce\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-31ed7ff5 elementor-widget elementor-widget-image\" data-id=\"31ed7ff5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e216dc7 elementor-widget elementor-widget-text-editor\" data-id=\"6e216dc7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tA Phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to enzalutamide or docetaxel alone in adults with mCRPC previously treated with abiraterone acetate.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-59482efa learn-more mevpro1Tile elementor-widget elementor-widget-button\" data-id=\"59482efa\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtn5\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6cfadaa8 learn-more mevpro1Tile elementor-widget elementor-widget-button\" data-id=\"6cfadaa8\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtnopen5\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6c27029f elementor-widget elementor-widget-html\" data-id=\"6c27029f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn5\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo5\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn5\").style.display = \"none\";\n      document.getElementById(\"morebtnopen5\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen5\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo5\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn5\").style.display = \"block\";\n      document.getElementById(\"morebtnopen5\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7c176cc9 bigtrial e-flex e-con-boxed e-con e-parent\" data-id=\"7c176cc9\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-695a13a0 detailsveritac elementor-widget elementor-widget-template\" data-id=\"695a13a0\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"moreinfo5\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"447\" class=\"elementor elementor-447\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tStudy details\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-1 is a Phase 3, randomized, open-label clinical trial to evaluate an investigational medicine called mevrometostat for men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed after treatment with abiraterone acetate. MEVPRO-1 will investigate whether mevrometostat in combination with enzalutamide is superior to either enzalutamide or docetaxel in prolonging radiographic progression-free survival in the mCRPC setting.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tApproximately 600 participants will be randomly assigned in a 1:1 ratio to Arm A or Arm B.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Investigational Arm A: <\/span><br>Mevrometostat 875 mg BID <span style=\"font-weight: 600;\">plus<\/span><br> enzalutamide 160 mg QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Comparator Arm B: <\/span><br \/>Study doctor\u2019s choice of enzalutamide 160 mg QD <span style=\"font-weight: 600;\">OR<\/span><br \/>docetaxel 75 mg\/m<sup>2<\/sup> IV every cycle (21 days) for up to a maximum of 10 cycles.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipants will receive investigational treatment until radiographic disease progression, unacceptable toxicity, protocol violation, withdrawal, or study termination. The length of participation in MEVPRO-1 will vary depending on how well participants tolerate the study treatment or time to disease progression. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period, and a 28- to 35-day safety follow-up. The treatment period in the study will consist of cycles of 3 weeks (docetaxel group) or 4 weeks (enzalutamide groups). Participants receiving investigational mevrometostat and enzalutamide or enzalutamide alone will attend 2 study visits in Cycles 1 and 2, then 1 study visit per cycle thereafter. Participants receiving standard-of-care docetaxel will attend 1 study visit per cycle for up to 10 cycles. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLong-term safety follow-up will consist of visits every 12 weeks from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipant eligibility \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Key inclusion criteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Male participants \u226518 years of age at screening.\n<\/li>\n \t<li>Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features. \n<\/li>\n\n \t<li>Metastatic disease in bone documented on bone scan or in soft tissue documented on CT\/MRI scan.\u202f \n<\/li>\n \t<li>Evidence of disease progression on or after treatment with at least 12 weeks of abiraterone acetate in the metastatic castration-sensitive prostate (mCSPC) cancer or first-line mCRPC setting.\n<\/li>\n\n\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Key exclusion criteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Treatment with chemotherapy since becoming castration-resistant.\n<\/li>\n \t<li>History of any other cancer in the last 3 years (except for some skin cancers or early stage cancers that have been cured).\n<\/li>\n \t<li>Clinically significant cardiovascular disease, kidney disease or liver disease.\n<\/li>\n \t<li>Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy, ARSi (including enzalutamide, apalutamide, darolutamide), PARP monotherapy or other systemic anti-cancer treatment.\n<\/li>\n \t<li>Major surgery or palliative localised radiation therapy within 14 days before randomisation.\n<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Please speak to the study team or a Pfizer Field Medical representative for a list of the full eligibility criteria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<span style=\"font-weight: 600;\">Thank you for considering this clinical trial for your patients.<\/span>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-1\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c3ac92f elementor-widget elementor-widget-html\" data-id=\"3c3ac92f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.addEventListener(\"DOMContentLoaded\", function() {\n      document.getElementById(\"closebtn\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n  \n      document.getElementById(\"morebtnopen\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n    });\n  <\/script>\n  \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4d6b27e1 smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"4d6b27e1\" data-element_type=\"container\" data-e-type=\"container\" id=\"MEVPRO-2\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-7e5f1952 e-con-full e-flex e-con e-child\" data-id=\"7e5f1952\" data-element_type=\"container\" data-e-type=\"container\" id=\"tactiveugov\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6939f0d0 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"6939f0d0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Not yet recruiting<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d1cd2fd elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"d1cd2fd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Recruiting<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b223d4f textBreast elementor-widget elementor-widget-text-editor\" data-id=\"b223d4f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-24d09b05 elementor-widget elementor-widget-text-editor\" data-id=\"24d09b05\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tFor your patients who have not tried hormone therapy or chemotherapy for metastatic castration-resistant prostate cancer\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2880ba5a elementor-align-left elementor-widget elementor-widget-button\" data-id=\"2880ba5a\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"govtactive\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/clinicaltrials.gov\/study\/NCT06629779?term=NCT06629779%20&#038;rank=1\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3075cce8 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"3075cce8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&#038;EUCT=2024-511652-40-00\" target=\"_blank\" rel=\"noopener\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1b8f53e e-con-full e-flex e-con e-child\" data-id=\"1b8f53e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-52ca76b6 elementor-widget elementor-widget-image\" data-id=\"52ca76b6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2f482ba8 elementor-widget elementor-widget-text-editor\" data-id=\"2f482ba8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tA Phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with mCRPC who have not tried hormonal therapy or chemotherapy in the castrate-resistant setting. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bcc563d learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"bcc563d\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtn4\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41caf536 learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"41caf536\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"morebtnopen3\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-355fbbde elementor-widget elementor-widget-html\" data-id=\"355fbbde\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn4\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo4\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn4\").style.display = \"none\";\n      document.getElementById(\"morebtnopen3\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen3\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo4\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn4\").style.display = \"block\";\n      document.getElementById(\"morebtnopen3\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2f15f81b bigtrial2 e-flex e-con-boxed e-con e-parent\" data-id=\"2f15f81b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-58d9eadb detailsveritac elementor-widget elementor-widget-template\" data-id=\"58d9eadb\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"moreinfo4\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"457\" class=\"elementor elementor-457\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tStudy details\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2 is a Phase 3, randomized, double-blind clinical trial of an investigational medicine called mevrometostat in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with mCRPC (metastatic castration resistant prostate cancer). \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-912f2e9 elementor-widget elementor-widget-text-editor\" data-id=\"912f2e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-2 will investigate whether mevrometostat plus enzalutamide can delay or prevent anti-androgen resistance to provide superior clinical benefit compared to enzalutamide alone in participants with mCRPC who have not tried hormone therapy or chemotherapy in the castration-resistant setting.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tApproximately 900 participants will be randomly assigned in a 1:1 ratio to Arm A or Arm B.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><span style=\"color: #097900; font-weight: 600;\">Investigational Arm A: <\/span><br \/>Mevrometostat 875 mg BID <span style=\"font-weight: 600;\">plus<\/span><br \/>enzalutamide 160 mg<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Comparator Arm B: <\/span><br>\nPlacebo tablets BID <span style=\"font-weight: 600;\">plus<\/span>\nenzalutamide 160 mg QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipants will receive investigational treatment until radiographic disease progression, unacceptable toxicity, protocol violation, withdrawal or study termination. The length of participation in MEVPRO-2 will vary depending on how well participants tolerate the study treatment or time to disease progression. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period, and a 28 to 35-day safety follow-up. The treatment period in the study will consist of cycles every 28 days. Participants will attend visits every 2 weeks until week 9, then every 4 weeks until week 53, and then every 8 weeks while receiving the study medicine. \n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLong-term safety follow-up will consist of visits every 12 weeks from the last dose until the study is complete, which may take many years, or until the participant withdraws consent.\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipant eligibility \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Key inclusion criteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Male participants \u226518 years of age at screening.\n<\/li>\n \t<li>Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.<\/li>\n \t<li>Metastatic disease in bone documented on bone scan or in soft tissue documented on CT\/MRI scan.\u202f\u00a0<\/li>\n \t<li>Progressive disease in the setting of medical or surgical castration as defined by meeting 1 or more of the following 3 criteria:<ul><li>PSA progression defined by a minimum of two rising PSA levels with an interval of \u22651 week between each determination, with a PSA value at the Screening visit being \u22652 \u03bcg\/L.<\/li>\n<li>Soft tissue disease progression as defined by RECIST 1.1.<\/li>\n<li>Bone disease progression defined by PCWG3 with 2 or more new metastatic bone lesions on a whole body radionuclide bone scan.<\/li><\/ul><\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Key exclusion criteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li>Participants must be treatment na\u00efve at the mCRPC stage, e.g., participants cannot have received any cytotoxic chemotherapy (includes but not limited to docetaxel), received ARSI\/ abiraterone acetate in mCRPC, mCSPC or non-metastatic PC. Prior docetaxel in mCSPC is allowed.\n<\/li>\n \t<li>History of any other cancer in the last 3 years (except for some skin cancers or early stage cancers that have been cured).\n<\/li>\n \t<li>Clinically significant cardiovascular disease, kidney disease or liver disease.\n<\/li>\n \t<li>Prior treatment for prostate cancer at any stage with any cytotoxic chemotherapy, radioligand therapy, ARSi (including enzalutamide, apalutamide, darolutamide), PARP monotherapy or other systemic anti-cancer treatment.\n<\/li>\n \t<li>Major surgery or palliative localised radiation therapy within 14 days before randomisation.\n<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Please speak to the study team or a Pfizer Field Medical representative for a list of the full eligibility criteria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 600;\">Thank you for considering this clinical trial for your patients.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-2\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c3ac92f elementor-widget elementor-widget-html\" data-id=\"3c3ac92f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.addEventListener(\"DOMContentLoaded\", function() {\n      document.getElementById(\"closebtn\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n  \n      document.getElementById(\"morebtnopen\").onclick = function() {\n        var moreInfoSection = document.getElementById(\"moreinfo\");\n        moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n        \/\/ Toggle visibility of morebtn and morebtnopen\n        document.getElementById(\"morebtn\").style.display = \"block\";\n        document.getElementById(\"morebtnopen\").style.display = \"none\";\n      };\n    });\n  <\/script>\n  \t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-26605ec smalltrial e-flex e-con-boxed e-con e-parent\" data-id=\"26605ec\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a2359a5 e-con-full e-flex e-con e-child\" data-id=\"a2359a5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-bef1867 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"bef1867\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M8 8L15.5 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><path d=\"M15.5 8L8 15.5\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Not yet recruiting<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-88680b2 elementor-align-start elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"88680b2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"23\" height=\"23\" viewbox=\"0 0 23 23\" fill=\"none\"><circle cx=\"11.5\" cy=\"11.5\" r=\"11.5\" fill=\"#097900\"><\/circle><path d=\"M10 7L14.5 11.5L10 16\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Recruiting<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-15edc24 textBreast elementor-widget elementor-widget-text-editor\" data-id=\"15edc24\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-3 \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f196d8d elementor-widget elementor-widget-text-editor\" data-id=\"f196d8d\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tFor your patients with metastatic castration-sensitive prostate cancer who have not received treatment for their castration-sensitive cancer, with the exception of androgen-deprivation (chemical or surgical) therapy \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-47889f4 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"47889f4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrials.gov<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-733b478 elementor-align-left elementor-widget elementor-widget-button\" data-id=\"733b478\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Clinicaltrialsregister.eu<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-71c0648 e-con-full e-flex e-con e-child\" data-id=\"71c0648\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d7e84ba elementor-widget elementor-widget-image\" data-id=\"d7e84ba\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"111\" height=\"76\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/result-1.svg\" class=\"attachment-full size-full wp-image-442\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d83ebaf elementor-widget elementor-widget-text-editor\" data-id=\"d83ebaf\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>A phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with treatment-na\u00efve mCSPC.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-117c6c3 learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"117c6c3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-right\" viewbox=\"0 0 320 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M285.476 272.971L91.132 467.314c-9.373 9.373-24.569 9.373-33.941 0l-22.667-22.667c-9.357-9.357-9.375-24.522-.04-33.901L188.505 256 34.484 101.255c-9.335-9.379-9.317-24.544.04-33.901l22.667-22.667c9.373-9.373 24.569-9.373 33.941 0L285.475 239.03c9.373 9.372 9.373 24.568.001 33.941z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-92fbfab learn-more mevpro2Tile elementor-widget elementor-widget-button\" data-id=\"92fbfab\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-size-sm\" role=\"button\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-chevron-down\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M207.029 381.476L12.686 187.132c-9.373-9.373-9.373-24.569 0-33.941l22.667-22.667c9.357-9.357 24.522-9.375 33.901-.04L224 284.505l154.745-154.021c9.379-9.335 24.544-9.317 33.901.04l22.667 22.667c9.373 9.373 9.373 24.569 0 33.941L240.971 381.476c-9.373 9.372-24.569 9.372-33.942 0z\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Learn More<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0287610 elementor-widget elementor-widget-html\" data-id=\"0287610\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\n    document.getElementById(\"morebtn6\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo55\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn6\").style.display = \"none\";\n      document.getElementById(\"morebtnopen4\").style.display = \"block\";\n    };\n  \n    document.getElementById(\"morebtnopen4\").onclick = function() {\n      var moreInfoSection = document.getElementById(\"moreinfo55\");\n      moreInfoSection.style.display = (moreInfoSection.style.display === \"none\" || moreInfoSection.style.display === \"\") ? \"block\" : \"none\";\n  \n      \/\/ Toggle visibility of morebtn and morebtnopen\n      document.getElementById(\"morebtn6\").style.display = \"block\";\n      document.getElementById(\"morebtnopen4\").style.display = \"none\";\n    };\n  <\/script>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1118ae3 bigtrial2 e-flex e-con-boxed e-con e-parent\" data-id=\"1118ae3\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3a0e637 detailsveritac elementor-widget elementor-widget-template\" data-id=\"3a0e637\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"template.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-template\">\n\t\t\t\t\t<div data-elementor-type=\"container\" data-elementor-id=\"587\" class=\"elementor elementor-587\" data-elementor-post-type=\"elementor_library\">\n\t\t\t\t<div class=\"elementor-element elementor-element-27aa089b detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"27aa089b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-f7b7d90 elementor-widget elementor-widget-text-editor\" data-id=\"f7b7d90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tStudy details\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1d10ba88 elementor-widget elementor-widget-text-editor\" data-id=\"1d10ba88\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tMEVPRO-3 is a phase 3, randomised, double-blind clinical trial of an investigational medicine called mevrometostat in combination with enzalutamide compared to a placebo in combination with enzalutamide in adults with mCRPC (metastatic castration-resistant prostate cancer).\u00a0\u00a0\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-912f2e9 elementor-widget elementor-widget-text-editor\" data-id=\"912f2e9\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>MEVPRO-3 will investigate whether mevrometostat plus enzalutamide can delay or prevent anti-androgen resistance to provide superior clinical benefit compared to enzalutamide alone in participants with mCRPC who have not tried hormone therapy or chemotherapy in the castration-resistant setting.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-30600248 elementor-widget elementor-widget-text-editor\" data-id=\"30600248\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tApproximately 1,000 participants will be randomly assigned in a 1:1 ratio to Arm A or Arm B.\u00a0\u00a0\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5c925d11 detailsveritav2 e-flex e-con-boxed e-con e-parent\" data-id=\"5c925d11\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-2c3b9a9a e-con-full e-flex e-con e-child\" data-id=\"2c3b9a9a\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80db81b elementor-widget elementor-widget-text-editor\" data-id=\"80db81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Investigational Arm A: <\/span><br>\nMevrometostat 875 mg twice daily (BID)<br> <span style=\"font-weight: 600;\">plus<\/span>\nenzalutamide 160 mg once daily (QD)<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-25fdc07 e-con-full e-flex e-con e-child\" data-id=\"25fdc07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d6e223f elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d6e223f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul>\n \t<li><span style=\"color: #097900; font-weight: 600;\">Control Arm B:  <\/span><br>\nPlacebo tablets BID <span style=\"font-weight: 600;\">plus<\/span>\nenzalutamide 160 mg QD<\/li>\n<\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-22d71a08 e-flex e-con-boxed e-con e-parent\" data-id=\"22d71a08\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ad7d7cc elementor-widget elementor-widget-text-editor\" data-id=\"2ad7d7cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Participants will receive investigational treatment until radiographic disease progression, unacceptable toxicity, protocol violation, withdrawal or study termination. The length of participation in MEVPRO-3 will vary depending on how well participants tolerate the investigational treatment or time to disease progression.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4e7b51a elementor-widget elementor-widget-text-editor\" data-id=\"4e7b51a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe study includes a 28-day screening period, the treatment period and a safety follow-up lasting between 28 and 35 days.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-024c71f elementor-widget elementor-widget-text-editor\" data-id=\"024c71f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe treatment period in the study will consist of cycles every 4 weeks (28 days). Participants will attend visits every 4 weeks until cycle 14 and then every 8 weeks thereafter while receiving the study medicine. Participants will have imaging assessments every 8 weeks until week 25, then every 12 weeks thereafter.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d537eca elementor-widget elementor-widget-text-editor\" data-id=\"d537eca\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Long-term safety follow-up will consist of visits every 8 weeks until week 25 then every 12 weeks thereafter until the study is complete, which may take many years or until the participant withdraws consent.\u00a0<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4445dbb5 e-con-full e-flex e-con e-parent\" data-id=\"4445dbb5\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t<div class=\"elementor-element elementor-element-610b58e0 elementor-widget elementor-widget-text-editor\" data-id=\"610b58e0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tParticipant eligibility \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f8244e5 elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5f8244e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"37\" height=\"38\" viewbox=\"0 0 37 38\" fill=\"none\"><path d=\"M35.8058 19.1635C35.8058 28.7761 28.0143 36.5685 18.4029 36.5685C8.79155 36.5685 1 28.7761 1 19.1635C1 9.55103 8.79155 1.75854 18.4029 1.75854\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M34.4319 4.04865L18.4029 23.5148L11.0753 17.5604\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Key inclusion criteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3419d371 elementor-widget elementor-widget-text-editor\" data-id=\"3419d371\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Male participants \u226518 years of age at screening.<\/li><li>Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.<\/li><li class=\"update-delete\">Metastatic disease in bone documented on bone scan or in soft tissue documented on CT\/MRI scan.\u202f<\/li><li>Metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesion(s) on CT or MRI scan (for soft tissue\/visceral disease).\u202f<br \/><ul class=\"full-dot\"><li>Measurable soft tissue\/visceral disease (per RECIST v1.1) is required if there is not an evaluable bone lesion (according to PCWG3 criteria).<\/li><li>For participants with measurable soft tissue disease only, regional lymph node disease (e.g. below aortic bifurcation) alone does not qualify the participant for the study.<\/li><li>PET and SPECT are not evaluable imaging modalities for this study.<\/li><li>A bone scan showing intense symmetric activity in the bones (referred to as a \u201csuperscan\u201d) is not considered evaluable.<\/li><\/ul><\/li><li>Participants must have ECOG PS 0 or 1.<\/li><li>Participants must not have received any cytotoxic chemotherapy, ARPI (e.g. enzalutamide, apalutamide, abiraterone acetate or darolutamide) or any other systemic anti-cancer therapies for mCSPC, with the following exceptions:<br \/><ul class=\"full-dot\"><li>ADT (chemical or surgical) must be started prior to randomisation and must continue throughout the study. Previous  therapy with up to 3 months of ADT (with or without anti-androgens) is allowed with no radiographic evidence of disease progression or rising PSA levels before Day 1.<\/li><li>Treatment with oestrogens, cyproterone acetate or first-generation anti-androgens is allowed until randomisation but must be discontinued prior to randomisation.<\/li><li>Participants may have received 1 course of palliative radiation or surgery for symptomatic control secondary to prostate cancer, which should be completed at least 2 weeks before randomisation.<br \/>Note: Radical prostatectomy or definitive radiotherapy to the primary prostate tumour for mCSPC with curative intent is not permitted.<\/li><\/ul><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ffec70a elementor-widget elementor-widget-text-editor\" data-id=\"ffec70a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-ffec70a{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3253b30c elementor-icon-list--layout-traditional elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"3253b30c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item\">\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-icon\">\n\t\t\t\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"38\" height=\"39\" viewbox=\"0 0 38 39\" fill=\"none\"><path d=\"M36.7946 19.2892C36.7946 29.4096 28.7624 37.5785 18.8973 37.5785C9.03215 37.5785 1 29.4096 1 19.2892C1 9.16892 9.03215 1 18.8973 1C28.7624 1 36.7946 9.16892 36.7946 19.2892Z\" stroke=\"#00009D\" stroke-width=\"2\"><\/path><path d=\"M9.94592 9.64453L28.3459 28.9338\" stroke=\"#097900\" stroke-width=\"2\"><\/path><path d=\"M28.5946 9.89832L9.69731 28.6799\" stroke=\"#097900\" stroke-width=\"2\"><\/path><\/svg>\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Key exclusion criteria:<\/span>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-39687a30 elementor-widget elementor-widget-text-editor\" data-id=\"39687a30\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-39687a30{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2efc049 elementor-widget elementor-widget-text-editor\" data-id=\"2efc049\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-2efc049{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51ce9c7 elementor-widget elementor-widget-text-editor\" data-id=\"51ce9c7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-51ce9c7{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6dbcba0 elementor-widget elementor-widget-text-editor\" data-id=\"6dbcba0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Prior treatment with:<br \/><ul class=\"full-dot\"><li>ADT in the adjuvant\/neoadjuvant setting where the completion of ADT was &lt;12 months before randomisation and the total duration of ADT was &gt;36 months.<\/li><li>ARPI such as abiraterone, apalutamide, darolutamide, enzalutamide or other investigational ARPI.<\/li><li>Cytochrome P17 enzyme inhibitors such as oral ketoconazole as anti-cancer treatments for prostate cancer.<\/li><li>Chemotherapy including docetaxel or immunotherapy for prostate cancer.<\/li><li>Radiopharmaceuticals (i.e. 177Lu-PSMA-617, radium-223).<\/li><li>CDK4\/6 inhibitors.<\/li><li>Any other anti-cancer treatment for metastatic prostate cancer excluding palliative radiotherapy\/surgery and ADT as discussed above.<\/li><\/ul><\/li><li>History of any other cancer in the last 3 years (except for some skin cancers or early stage cancers that have been cured).<\/li><li>Clinically significant cardiovascular disease, kidney disease or liver disease.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-73e39f3 elementor-widget elementor-widget-text-editor\" data-id=\"73e39f3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<style>.elementor-element-73e39f3{display:none !important}<\/style>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bbaac08 elementor-widget elementor-widget-text-editor\" data-id=\"bbaac08\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>Prior treatment with:<br \/><ul class=\"full-dot\"><li>ADT in the adjuvant\/neoadjuvant setting, where the completion of ADT was &lt;12 months prior to randomisation and the total duration of ADT was &gt;36 months.<\/li><li>ARPI such as abiraterone, apalutamide, darolutamide, enzalutamide or other investigational ARPI.<\/li><li>Cytochrome P17 enzyme inhibitors such as oral ketoconazole as anti-cancer treatments for prostate cancer.<\/li><li>Chemotherapy including docetaxel or immunotherapy for prostate cancer.<\/li><li>Radiopharmaceuticals (i.e. 177Lu-PSMA-617, radium-223).<\/li><li>CDK4\/6 inhibitors.<\/li><li>Any other anti-cancer treatment for metastatic prostate cancer excluding palliative radiotherapy\/surgery and ADT as discussed above.<\/li><\/ul><\/li><li>History of any other cancer in the last 3 years (except for some skin cancers or early stage cancers that have been cured).<\/li><li>Clinically significant cardiovascular disease, kidney disease or liver disease.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-713f9797 e-flex e-con-boxed e-con e-parent\" data-id=\"713f9797\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f78d127 elementor-widget elementor-widget-text-editor\" data-id=\"2f78d127\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Please speak to the study team or a Pfizer Field Medical representative for a list of the full eligibility criteria.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-22c06a92 elementor-widget elementor-widget-text-editor\" data-id=\"22c06a92\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 600;\">Thank you for considering this clinical trial for your patients.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4990c650 elementor-align-right IDs-btn elementor-widget elementor-widget-button\" data-id=\"4990c650\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"closebtn\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"#MEVPRO-3\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t<span class=\"elementor-button-icon\">\n\t\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"42\" height=\"42\" viewbox=\"0 0 42 42\" fill=\"none\"><circle cx=\"21\" cy=\"21\" r=\"21\" fill=\"#097900\"><\/circle><path d=\"M13 24L21 16L29 24\" stroke=\"white\" stroke-width=\"2\" stroke-linecap=\"round\" stroke-linejoin=\"round\"><\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5958faa e-flex e-con-boxed e-con e-parent\" data-id=\"5958faa\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a2b556e e-con-full e-flex e-con e-child\" data-id=\"a2b556e\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-03d3426 elementor-widget elementor-widget-heading\" data-id=\"03d3426\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Do you have patients with metastatic prostate cancer in your care?<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1a9e3e1 e-con-full e-flex e-con e-child\" data-id=\"1a9e3e1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div class=\"elementor-element elementor-element-80251c2 e-con-full e-flex e-con e-child\" data-id=\"80251c2\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-24624e5 elementor-widget elementor-widget-image\" data-id=\"24624e5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"77\" height=\"98\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/10\/medical-record-1.svg\" class=\"attachment-full size-full wp-image-455\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-151dd15 e-con-full e-flex e-con e-child\" data-id=\"151dd15\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-095411b elementor-widget elementor-widget-text-editor\" data-id=\"095411b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tTo learn more about Pfizer\u2019s MEVPRO Prostate Cancer Clinical Trials and how to refer potentially eligible patients, please complete the Contact Form and a member of the Pfizer Field Medical team will contact you. \t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-dc65bb3 elementor-widget elementor-widget-button\" data-id=\"dc65bb3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"\/en-nz\/hcp\/#contactform\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Contact Form<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-00be4aa e-flex e-con-boxed e-con e-parent\" data-id=\"00be4aa\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-21c39cd elementor-widget elementor-widget-heading\" data-id=\"21c39cd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Thank you for considering Pfizer\u2019s MEVPRO Prostate Cancer Clinical Trials for your patients.  <\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b188a5f e-flex e-con-boxed e-con e-parent\" data-id=\"b188a5f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-11a6f1c e-con-full e-flex e-con e-child\" data-id=\"11a6f1c\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-d60c0ec elementor-widget elementor-widget-text-editor\" data-id=\"d60c0ec\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>How clinical trials work<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6bfe395 elementor-widget elementor-widget-image\" data-id=\"6bfe395\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/en-nz\/clinical-trials\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-572cd84 e-con-full e-flex e-con e-child\" data-id=\"572cd84\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-53bbb16 elementor-widget elementor-widget-text-editor\" data-id=\"53bbb16\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tSteps to join a clinical trial\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-a2e0214 elementor-widget elementor-widget-image\" data-id=\"a2e0214\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/en-nz\/steps-to-join\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-87bed07 e-con-full e-flex e-con e-child\" data-id=\"87bed07\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-94f0d2f elementor-widget elementor-widget-text-editor\" data-id=\"94f0d2f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tProtecting your safety &#038; privacy\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2b7ca47 elementor-widget elementor-widget-image\" data-id=\"2b7ca47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/en-nz\/privacy\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-b20ecc1 e-con-full e-flex e-con e-child\" data-id=\"b20ecc1\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e92688e elementor-widget-tablet__width-inherit elementor-widget elementor-widget-text-editor\" data-id=\"e92688e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tFAQ\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-61b0a47 elementor-widget elementor-widget-image\" data-id=\"61b0a47\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"\/en-nz\/faq\/\">\n\t\t\t\t\t\t\t<img decoding=\"async\" width=\"49\" height=\"49\" src=\"https:\/\/mevproclinicaltrials.com\/wp-content\/uploads\/2024\/09\/preFooter.svg\" class=\"attachment-large size-large wp-image-172\" alt=\"\" \/>\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Pfizer MEVPRO Prostate Cancer Clinical Trials Help advance metastatic prostate cancer treatment research Explore Pfizer\u2019s MEVPRO Clinical Trials as potential options for your patients Not yet recruiting Recruiting MEVPRO-1For your patients with abiraterone-resistant metastatic prostate cancer Clinicaltrials.gov Clinicaltrialsregister.eu A Phase 3 clinical trial evaluating the investigational medicine (mevrometostat) in combination with enzalutamide compared to enzalutamide [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"single_temp_hcp_trial.php","meta":{"footnotes":""},"class_list":["post-360","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/pages\/360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/comments?post=360"}],"version-history":[{"count":0,"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/pages\/360\/revisions"}],"wp:attachment":[{"href":"https:\/\/mevproclinicaltrials.com\/en-nz\/wp-json\/wp\/v2\/media?parent=360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}